Azadeh Cheraghchi-Bashi

Azadeh Cheraghchi-Bashi

Auto-generated profile, based on publicly available information

Azadeh Cheraghchi-Bashi

AstraZeneca 1 Bioscience, Oncology R&D Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
MLMandy Lawson
Mandy Lawson
NCNatalie Cureton
Natalie Cureton
SRSusana Ros
Susana Ros
ACAzadeh Cheraghchi-Bashi
Azadeh Cheraghchi-Bashi
JUJelena Urosevic
Jelena Urosevic
LCLarissa S. Carnevalli
Larissa S. Carnevalli
Oral selective estrogen receptor degraders (SERD) could become the backbone of endocrine therapy (ET) for estrogen receptor–positive (ER+) breast cancer, as they achieve greater inhibition of ER-driven cancers than current ETs and overcome key resistance mechanisms. In this study, we evaluated the preclinical pharmacology and efficacy of the next-generation oral SERD camizestrant (AZD9833) and assessed ER–co-targeting strategies by combining camizestrant with CDK4/6 inhibitors (CDK4/6i) and PI3K/AKT/mTOR-targeted therapy in models of progression on CDK4/6i and/or ET. Camizestrant demonstrated robust and selective ER degradation, modulated ER-regulated gene expression, and induced complete ER antagonism and significant antiproliferation activity in ESR1 wild-type (ESR1wt) and mutant (ESR1m) breast cancer cell lines and patient-derived xenograft (PDX) models. Camizestrant also delivered strong antitumor activity in fulvestrant-resistant ESR1wt and ESR1m PDX models. Evaluation of camizestrant in combination with CDK4/6i (palbociclib or abemaciclib) in CDK4/6-naive and -resistant models, as well as in combination with PI3Kαi (alpelisib), mTORi (everolimus), or AKTi (capivasertib), indicated that camizestrant was active with CDK4/6i or PI3K/AKT/mTORi and that antitumor activity was further increased by the triple combination. The response was observed independently of PI3K pathway mutation status. Overall, camizestrant shows strong and broad antitumor activity in ER+ breast cancer as a monotherapy and when combined with CDK4/6i and PI3K/AKT/mTORi. Significance: Camizestrant, a next-generation oral SERD, shows promise in preclinical models of ER+ breast cancer alone and in combination with CDK4/6 and PI3K/AKT/mTOR inhibitors to address endocrine resistance, a current barrier to treatment.

8 March 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ABAzadeh C. Bashi
Azadeh C. Bashi
ECElizabeth A. Coker
Elizabeth A. Coker
KBKrishna C. Bulusu
Krishna C. Bulusu
PJPatricia Jaaks
Patricia Jaaks
CCClaire Crafter
Claire Crafter
MGMathew J. Garnett
Mathew J. Garnett
Oncology drug combinations can improve therapeutic responses and increase treatment options for patients. The number of possible combinations is vast and responses can be context-specific. Systematic screens can identify clinically relevant, actionable combinations in defined patient subtypes. We present data for 109 anticancer drug combinations from AstraZeneca's oncology small molecule portfolio screened in 755 pan-cancer cell lines. Combinations were screened in a 7 × 7 concentration matrix, with more than 4 million measurements of sensitivity, producing an exceptionally data-rich resource. We implement a new approach using combination Emax (viability effect) and highest single agent (HSA) to assess combination benefit. We designed a clinical translatability workflow to identify combinations with clearly defined patient populations, rationale for tolerability based on tumor type and combination-specific “emergent” biomarkers, and exposures relevant to clinical doses. We describe three actionable combinations in defined cancer types, confirmed in vitro and in vivo, with a focus on hematologic cancers and apoptotic targets. Significance: We present the largest cancer drug combination screen published to date with 7 × 7 concentration response matrices for 109 combinations in more than 750 cell lines, complemented by multi-omics predictors of response and identification of “emergent” combination biomarkers. We prioritize hits to optimize clinical translatability, and experimentally validate novel combination hypotheses. This article is featured in Selected Articles from This Issue, p. 695

19 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
ACAzadeh Cheraghchi-Bashi
Azadeh Cheraghchi-Bashi
CPChristine A. Parker
Christine A. Parker
ECEd Curry
Ed Curry
JSJean-Frederic Salazar
Jean-Frederic Salazar
HGHatice Gungor
Hatice Gungor
ESEuan A. Stronach
Euan A. Stronach
Our identification of dysregulation of the AKT pathway in ovarian cancer as a platinum resistance specific event led to a comprehensive analysis of in vitro, in vivo and clinical behaviour of the AKT inhibitor GSK2141795. Proteomic biomarker signatures correlating with effects of GSK2141795 were developed using in vitro and in vivo models, well characterised for related molecular, phenotypic and imaging endpoints. Signatures were validated in temporally paired biopsies from patients treated with GSK2141795 in a clinical study. GSK2141795 caused growth-arrest as single agent in vitro, enhanced cisplatin-induced apoptosis in vitro and reduced tumour volume in combination with platinum in vivo. GSK2141795 treatment in vitro and in vivo resulted in ~50-90% decrease in phospho-PRAS40 and 20-80% decrease in fluoro-deoxyglucose (FDG) uptake. Proteomic analysis of GSK2141795 in vitro and in vivo identified a signature of pathway inhibition including changes in AKT and p38 phosphorylation and total Bim, IGF1R, AR and YB1 levels. In patient biopsies, prior to treatment with GSK2141795 in a phase 1 clinical trial, this signature was predictive of post-treatment changes in the response marker CA125. Development of this signature represents an opportunity to demonstrate the clinical importance of AKT inhibition for re-sensitisation of platinum resistant ovarian cancer to platinum.

26 March 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
ABAzadeh C. Bashi
Azadeh C. Bashi
TPTheresa A. Proia
Theresa A. Proia
MLMandy Lawson
Mandy Lawson
ANAnders Nelson
Anders Nelson
LILucy Ireland
Lucy Ireland
SBSimon T. Barry
Simon T. Barry
Trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor, is approved for the treatment of HER2-positive (HER2+) and HER2-low breast cancer as well as HER2-high gastric and HER2-mutant lung cancer tumors. The AKT inhibitor capivasertib is approved for the treatment of HER2− estrogen receptor–positive breast cancer with alterations in PIK3CA, PTEN, and AKT-1. The potential for the combination of T-DXd with AKT inhibition to enhance antitumor activity was explored in HER2+ or HER2-low preclinical models. In vitro, combination activity was observed in both HER2-high– and HER2-low–expressing breast cancer as well as in gastric, endometrial, and ovarian models, irrespective of HER2 expression level or PI3K–AKT status pathway alterations. The T-DXd–capivasertib combination effect translated in vivo with increased antitumor benefit in HER2-expressing, PI3K–AKT pathway–altered tumor xenografts when compared with the combination of trastuzumab and capivasertib. In cell lines sensitive to the combination, combining T-DXd with capivasertib targeted complimentary pathways which resulted in disruption of the cell cycle and increased cell death. These results suggest that T-DXd combined with capivasertib has the potential to be active in HER2+ as well as HER2-low tumors independent of PI3K pathway alteration status.

2 July 2026
Verified
Other
Open access
ABAzadeh C. Bashi
Azadeh C. Bashi
TPTheresa A. Proia
Theresa A. Proia
MLMandy Lawson
Mandy Lawson
ANAnders Nelson
Anders Nelson
LILucy Ireland
Lucy Ireland
SBSimon T. Barry
Simon T. Barry
Supplementary Table 2. Antibody details

2 July 2026
Verified
Other
Open access
ABAzadeh C. Bashi
Azadeh C. Bashi
TPTheresa A. Proia
Theresa A. Proia
MLMandy Lawson
Mandy Lawson
ANAnders Nelson
Anders Nelson
LILucy Ireland
Lucy Ireland
SBSimon T. Barry
Simon T. Barry
Supplementary Figure 8. Active cell cycle distribution analysis of KPL4, EFM19 and KPL4 cells treated with T-DXd or capivasertib monotherapy, or the combination